Sleep Wake Advisor

  • Home
  • Sleep Wake Advisor

Sleep Wake Advisor Sleep-Wake Advisor is aimed at helping clinicians with the latest research and resources to assist in the diagnosis and treatment of sleep-wake disorders.

The Food and Drug Administration ( ) has accepted for filing the New Drug Application (NDA) for AXS-12 (reboxetine) for ...
22/07/2026

The Food and Drug Administration ( ) has accepted for filing the New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in .

Supported by phase 3 SYMPHONY and ENCORE trial data, AXS-12 significantly reduced weekly cataplexy attacks and improved daytime sleepiness and cognition.

, a regulated prediction market exchange, has launched a pilot program that allows users to bet on the outcomes of clin...
22/07/2026

, a regulated prediction market exchange, has launched a pilot program that allows users to bet on the outcomes of clinical trials and Food and Drug Administration ( ) regulatory decisions.

A new pilot program uses regulated prediction markets and independent data verification to establish public probabilities for trial endpoints and FDA decisions.

At the SLEEP 2026 Conference, Dr Daniel Barone discusses key findings, including a new pill for and in sleep medicin...
15/07/2026

At the SLEEP 2026 Conference, Dr Daniel Barone discusses key findings, including a new pill for and in sleep medicine.

In an exclusive interview with us, Dr Barone discusses key findings from the SLEEP 2026 conference.

Exercising during the day is associated with an increased risk for nocturnal in adults with .
15/07/2026

Exercising during the day is associated with an increased risk for nocturnal in adults with .

Researchers evaluated the effect of daytime physical activity on the risk for nocturnal hypoglycemia in adults with type 1 diabetes.

The has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adult...
15/07/2026

The has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea ( ).

The FDA's acceptance of the NDA for AD109 marks a pivotal clinical milestone toward introducing the first oral pharmacotherapy designed to target the neuromuscular causes of obstructive sleep apnea.

Patients with idiopathic intracranial have a high prevalence of comorbid , suggesting that clinicians should routinel...
10/07/2026

Patients with idiopathic intracranial have a high prevalence of comorbid , suggesting that clinicians should routinely refer this population for diagnostic sleep studies.

Researchers conducted a meta-analysis to evaluate the prevalence of obstructive sleep apnea in patients with idiopathic intracranial hypertension.

Better multidimensional health is bidirectionally associated with reduced daily and night pain and morning stiffness...
10/07/2026

Better multidimensional health is bidirectionally associated with reduced daily and night pain and morning stiffness.

Researchers evaluated the bidirectional association between daily sleep health and pain severity in adults with rheumatoid arthritis.

The FDA has granted Orphan Drug designation to , an investigational orexin 2 receptor agonist, for idiopathic .
24/06/2026

The FDA has granted Orphan Drug designation to , an investigational orexin 2 receptor agonist, for idiopathic .

Alixorexton is also currently being evaluated for the treatment of narcolepsy type 1 and type 2 in the phase 3 Brilliance clinical program.

A meta-analysis indicated that evening chronotypes vs control participants have a higher prevalence of chronic and con...
24/06/2026

A meta-analysis indicated that evening chronotypes vs control participants have a higher prevalence of chronic and consistently poorer quality.

In a systematic review and meta-analysis, researchers evaluated the observed associations between chronotype and pain outcomes.

Pure autonomic failure may represent a prodromal manifestation of , with Lewy bodies, and multiple system atrophy, wi...
10/06/2026

Pure autonomic failure may represent a prodromal manifestation of , with Lewy bodies, and multiple system atrophy, with an approximately 5% annual phenoconversion rate.

Researchers evaluated phenoconversion rates and clinical predictors of progression from pure autonomic failure to central α-synucleinopathies.

Address


Website

Alerts

Be the first to know and let us send you an email when Sleep Wake Advisor posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

  • Want your business to be the top-listed Media Company?

Share